Literature DB >> 23933495

Association of ITPA polymorphisms rs6051702/rs1127354 instead of rs7270101/rs1127354 as predictor of ribavirin-associated anemia in chronic hepatitis C treated patients.

Antonio D'Avolio1, Amedeo De Nicolò, Jessica Cusato, Alessia Ciancio, Lucio Boglione, Silvia Strona, Giuseppe Cariti, Giulia Troshina, Gian Paolo Caviglia, Antonina Smedile, Mario Rizzetto, Giovanni Di Perri.   

Abstract

Functional variants rs7270101 and rs1127354 of inosine triphosphatase (ITPA) were recently found to protect against ribavirin (RBV)-induced hemolytic anemia. However, no definitive data are yet available on the role of no functional rs6051702 polymorphism. Since a simultaneous evaluation of the three ITPA SNPs for hemolytic anemia has not yet been investigated, we aimed to understand the contribution of each SNPs and its potential clinical use to predict anemia in HCV treated patients. A retrospective analysis included 379 HCV treated patients. The ITPA variants rs6051702, rs7270101 and rs1127354 were genotyped and tested for association with achieving anemia at week 4. We also investigated, using multivariate logistic regression, the impact of each single and paired associated polymorphism on anemia onset. All SNPs were associated with Hb decrease. The carrier of at least one variant allele in the functional ITPA SNPs was associated with a lower decrement of Hb, as compared to patients without a variant allele. In multivariate logistic regression analyses the carrier of a variant allele in the rs6051702/rs1127354 association (OR=0.11, p=1.75×10(-5)) and Hb at baseline (OR=1.51, p=1.21×10(-4)) were independently associated with protection against clinically significant anemia at week 4. All ITPA polymorphisms considered were shown to be significantly associated with anemia onset. A multivariate regression model based on ITPA genetic polymorphisms was developed for predicting the risk of anemia. Considering the characterization of pre-therapy anemia predictors, rs6051702 SNP in association to rs1127354 is more informative in order to avoid this relevant adverse event.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adverse event; Anemia; HCV; Hb; IQR; ITP; ITPA; PEG/IFN; RBV; Ribavirin; SNPs; SVR; Single nucleotide polymorphism; TDM; WT; haemoglobin; hepatitis C virus; inosine triphosphatase; inosine triphosphate; inter-quartile range; pegylated interferon; ribavirin; single nucleotide polymorphisms; sustained virological response; therapeutic drug monitoring; wild type

Mesh:

Substances:

Year:  2013        PMID: 23933495     DOI: 10.1016/j.antiviral.2013.07.021

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  4 in total

1.  Genotyping NUDT15 can predict the dose reduction of 6-MP for children with acute lymphoblastic leukemia especially at a preschool age.

Authors:  Hisato Suzuki; Hiroko Fukushima; Ryoko Suzuki; Sho Hosaka; Yuni Yamaki; Chie Kobayashi; Aiko Sakai; Kazuo Imagawa; Atsushi Iwabuchi; Ai Yoshimi; Tomohei Nakao; Keisuke Kato; Masahiro Tsuchida; Nobutaka Kiyokawa; Kazutoshi Koike; Emiko Noguchi; Takashi Fukushima; Ryo Sumazaki
Journal:  J Hum Genet       Date:  2016-05-19       Impact factor: 3.172

2.  Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis.

Authors:  Daniel Pineda-Tenor; Mónica García-Álvarez; María A Jiménez-Sousa; Sonia Vázquez-Morón; Salvador Resino
Journal:  J Transl Med       Date:  2015-10-06       Impact factor: 5.531

Review 3.  A disease spectrum for ITPA variation: advances in biochemical and clinical research.

Authors:  Nicholas E Burgis
Journal:  J Biomed Sci       Date:  2016-10-22       Impact factor: 8.410

4.  The ITPA and C20orf194 Polymorphisms and Hematological Changes During Treatment With Pegylated-Interferon Plus Ribavirin in Patients With Chronic Hepatitis C.

Authors:  Mohammad Pouryasin; Maryam Keshvari; Heidar Sharafi; Seyed Moayed Alavian; Bita Behnava; Seyed Ehsan Alavian; Ali Pouryasin
Journal:  Hepat Mon       Date:  2016-02-20       Impact factor: 0.660

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.